Viridian Therapeutics, Inc./DE Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Viridian Therapeutics, Inc./DE (VRDN) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -1.20% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-02-26
- Viridian Therapeutics, Inc./DE effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was -1.20%.
- Viridian Therapeutics, Inc./DE effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -3.00%.
- Viridian Therapeutics, Inc./DE effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -0.70%.
- Viridian Therapeutics, Inc./DE effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -0.80%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2025-12-31 | -1.20% 10-K · filed 2026-02-26 |
| 2024-12-31 | -3.00% 10-K · filed 2026-02-26 |
| 2023-12-31 | -0.70% 10-K · filed 2026-02-26 |
| 2022-12-31 | -0.80% 10-K · filed 2025-03-03 |
| 2021-12-31 | 0.00% 10-K · filed 2024-02-27 |
| 2020-12-31 | -0.90% 10-K · filed 2022-03-11 |
| 2019-12-31 | -3.90% 10-K · filed 2021-03-26 |
| 2018-12-31 | -1.00% 10-K · filed 2020-03-13 |
| 2017-12-31 | 1.90% 10-K · filed 2019-03-14 |
| 2016-12-31 | -0.40% 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |